EU-trans Tasman bridge strengthened by UK's BIVDA (British In Vitro Diagnostics Association)
This article was originally published in Clinica
As the new trans Tasman regulatory region gears up for major reforms that will see the first IVD-specific regulations for Australia and New Zealand, stronger links and synergies are developing with the diagnostics market of the EU. So said Doris-Ann Williams, director general of the British In Vitro Diagnostics Association (BIVDA), to Clinica, ahead of a regulatory meeting being hosted by the Medical Industry Association of New Zealand (MIANZ).
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.